Thomas Strecker
Overview
Explore the profile of Thomas Strecker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watson C, Gsell P, Hall Y, Camacho A, Riveros X, Enwere G, et al.
BMC Med
. 2024 Nov;
22(1):523.
PMID: 39511527
Background: Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that...
2.
Strecker T, Siegle M, Bremer F
SAGE Open Med Case Rep
. 2024 Oct;
12:2050313X241282761.
PMID: 39371391
Hyperglycemia and diabetic ketoacidosis are serious and life-threatening emergencies in diabetes patients. Early recognition of the symptoms of these disorders and their management are essential. Therapy is adequate rehydration, insulin...
3.
Hofmann N, Bartkuhn M, Becker S, Biedenkopf N, Bottcher-Friebertshauser E, Brinkrolf K, et al.
J Virol
. 2024 Sep;
98(10):e0093524.
PMID: 39283124
The large group of negative-strand RNA viruses (NSVs) comprises many important pathogens. To identify conserved patterns in host responses, we systematically compared changes in the cellular RNA levels after infection...
4.
Brouwer P, Perrett H, Beaumont T, Nijhuis H, Kruijer S, Burger J, et al.
Cell Rep
. 2024 Sep;
43(9):114708.
PMID: 39243373
Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus...
5.
Donnellan F, Rayaprolu V, Rijal P, ODowd V, Parvate A, Callaway H, et al.
bioRxiv
. 2024 Jul;
PMID: 38979279
Ebolavirus disease (EVD) is caused by multiple species of . Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused...
6.
Zhang Z, Takenaga T, Fehling S, Igarashi M, Hirokawa T, Muramoto Y, et al.
J Virol
. 2024 May;
98(7):e0071424.
PMID: 38809021
Lassa virus (LASV) is the causative agent of human Lassa fever which in severe cases manifests as hemorrhagic fever leading to thousands of deaths annually. However, no approved vaccines or...
7.
Bore J, Timothy J, Tipton T, Kekoura I, Hall Y, Hood G, et al.
Nat Commun
. 2024 May;
15(1):4171.
PMID: 38755147
Human Ebola virus (EBOV) outbreaks caused by persistent EBOV infection raises questions on the role of zoonotic spillover in filovirus epidemiology. To characterise filovirus zoonotic exposure, we collected cross-sectional serum...
8.
Brouwer P, Perrett H, Beaumont T, Nijhuis H, Kruijer S, Burger J, et al.
bioRxiv
. 2024 Jan;
PMID: 38187682
Lassa fever continues to be a major public health burden in endemic countries in West Africa, yet effective therapies or vaccines are lacking. The isolation of potent and protective neutralizing...
9.
Strecker T, Treutlein C, Agaimy A, Wehrfritz A
SAGE Open Med Case Rep
. 2023 Oct;
11:2050313X231207202.
PMID: 37860283
Streptococcal toxic shock syndrome is a severe, invasive and life-threatening infection associated with a high risk of rapid multiorgan failure. It is associated with high morbidity and mortality. Streptococcal toxic...
10.
Oestereich L, Muller-Krauter H, Pallasch E, Strecker T
Viruses
. 2023 Jul;
15(7).
PMID: 37515124
Background: Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are considered a promising treatment strategy in...